ESC 糖尿病合并心血管疾病管理指南解读
黄坤， 廖玉华 - 临床心血管病杂志, 2023 - lcxxg.whuhzzs.com
… European Society of Cardiology congress in August 2023. The guild line pay attention to
the interaction between cardiovascular disease, chronic kidney disease and diabetes mellitus. …
the interaction between cardiovascular disease, chronic kidney disease and diabetes mellitus. …
[PDF][PDF] 心肌收缩力调节器的研究进展
沈月英， 王楠， 张玥 - 2023 - xinyixue.cn
… Cardiac contractility modulation (CCM)is a novel treatment method for patients with heart …
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med,2017,…
Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med,2017,…
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 …
H Tan, W Li, Z Huang, Y Han, X Huang, D Li… - Cardiology and …, 2023 - Springer
… (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and … patients with
primary hypercholesterolemia and mixed dyslipidemia at different levels of cardiovascular disease …
primary hypercholesterolemia and mixed dyslipidemia at different levels of cardiovascular disease …
冠心病持续性心房颤动患者中医证候学特征研究
贾秋蕾， 肖响， 胡元会， 朱宝琛， 韩文兵 - 北京中医药, 2023 - bjtcm.net
… TCM syndrome characteristics of coronary artery disease (CAD) patients accompanied
with persistent atrial fibrillation (PeAF).,Methods,2,A total of 282 CAD patients with PeAF were …
with persistent atrial fibrillation (PeAF).,Methods,2,A total of 282 CAD patients with PeAF were …
[HTML][HTML] 外周动脉疾病抗栓治疗进展
陈媛， 袁忠明 - Advances in Clinical Medicine, 2023 - hanspub.org
… PAD is closely related to diabetes, hyperlipidemia, hypertension, smoking and other risk …
risk of other cardiovascular events and cardiovascular death. Therefore, patients with PAD …
risk of other cardiovascular events and cardiovascular death. Therefore, patients with PAD …
非奈利酮、 钠-葡萄糖共转运蛋白-2 抑制剂及两者联合应用对心肾保护作用的研究进展
周明双， 郑绍莹， 张雯， 李雪， 张芹， 赵雅静 - 临床心血管病杂志, 2024 - lcxxg.whuhzzs.com
… 2023 ESC糖尿病合并心血管疾病管理指南解读[J]. 临床心血管病杂志, 2023, 39(10): 753-755.
https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2023.10.004 …
https://lcxxg.whuhzzs.com/article/doi/10.13201/j.issn.1001-1439.2023.10.004 …
SGLT2 抑制剂在常见心血管疾病中应用的研究进展.
张辉， 王利， 邓龙， 刘传斌 - Practical Pharmacy & Clinical …, 2023 - search.ebscohost.com
… cause of disability and death in patients with diabetes. Sodium-glucose co-transporter 2 (SGLT2…
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur …
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur …
[HTML][HTML] SGLT2i 与GLP-1RAs 的联合应用在老年T2DM 患者中心血管获益价值分析
代琳艳， 李兴升 - Advances in Clinical Medicine, 2023 - hanspub.org
… patients with type 2 diabetes usually have a higher risk of adverse cardiovascular events …
2019年欧洲心脏病学会与欧洲糖尿病研究协会联合制定的ESC指南建议[44] ,无论对有无二甲双胍…
2019年欧洲心脏病学会与欧洲糖尿病研究协会联合制定的ESC指南建议[44] ,无论对有无二甲双胍…
慢性肾脏病合并心力衰竭患者的防治
朱婷婷， 宣铭杨， 饶向荣 - 临床肾脏病杂志, 2023 - lcszb.com
… disease (CKD) is associated with an elevated risk of cardiovascular disease, particularly in
the form of heart … 年ESC 对有症状的HFrEF 患 者的指南提供了I 类建议[11],ACEI/血管紧张素受体…
the form of heart … 年ESC 对有症状的HFrEF 患 者的指南提供了I 类建议[11],ACEI/血管紧张素受体…